CERo Therapeutics (NASDAQ:CERO) Earns “Buy” Rating from D. Boral Capital

CERo Therapeutics (NASDAQ:CERO)‘s stock had its “buy” rating reissued by stock analysts at D. Boral Capital in a research note issued to investors on Monday,Benzinga reports. They presently have a $30.00 target price on the stock. D. Boral Capital’s target price would indicate a potential upside of 288.10% from the company’s current price.

CERO has been the topic of several other research reports. Maxim Group started coverage on CERo Therapeutics in a report on Monday, May 19th. They issued a “buy” rating and a $60.00 price target on the stock. D Boral Capital raised CERo Therapeutics from a “hold” rating to a “strong-buy” rating in a research note on Monday, June 23rd.

CERo Therapeutics Trading Up 1.2%

Shares of NASDAQ:CERO opened at $7.73 on Monday. The business’s 50 day simple moving average is $8.95 and its two-hundred day simple moving average is $18.62. CERo Therapeutics has a 52-week low of $6.71 and a 52-week high of $895.40.

CERo Therapeutics (NASDAQ:CERO) last announced its quarterly earnings results on Thursday, May 15th. The company reported ($31.80) earnings per share (EPS) for the quarter.

Institutional Trading of CERo Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the stock. Parallel Advisors LLC purchased a new stake in shares of CERo Therapeutics in the first quarter worth approximately $161,000. Armistice Capital LLC purchased a new stake in shares of CERo Therapeutics during the first quarter valued at approximately $228,000. Finally, ARCH Venture Management LLC increased its position in shares of CERo Therapeutics by 550.4% during the fourth quarter. ARCH Venture Management LLC now owns 9,393,561 shares of the company’s stock valued at $564,000 after acquiring an additional 7,949,265 shares during the last quarter. 29.64% of the stock is owned by hedge funds and other institutional investors.

CERo Therapeutics Company Profile

CERo Therapeutics Holdings, Inc, an immunotherapy company, focuses on advancing the development of engineered T cell therapeutics for the treatment of cancer. Its lead program in hematologic malignancies targets an Eat Me signal upregulated on B cell and myeloid tumors. The company is based in South San Francisco, California.